{"id":28674,"date":"2022-11-15T11:02:44","date_gmt":"2022-11-15T10:02:44","guid":{"rendered":"https:\/\/master-3.corporate.ferring.tech\/?p=28674"},"modified":"2022-11-15T12:08:47","modified_gmt":"2022-11-15T11:08:47","slug":"ferring-pharmaceuticals-and-gubra-announce-strategic-collaboration-within-inflammatory-bowel-disease-ibd","status":"publish","type":"post","link":"https:\/\/www.ferring.com\/ferring-pharmaceuticals-and-gubra-announce-strategic-collaboration-within-inflammatory-bowel-disease-ibd\/","title":{"rendered":"Ferring Pharmaceuticals and Gubra announce collaboration within Inflammatory Bowel Disease (IBD)"},"content":{"rendered":"[spb_boxed_content type=&#8221;coloured&#8221; box_link_target=&#8221;_self&#8221; padding_vertical=&#8221;0&#8243; padding_horizontal=&#8221;0&#8243; width=&#8221;1\/1&#8243; el_position=&#8221;first last&#8221;]\n<h2 style=\"color: #0088ce\">Ferring Pharmaceuticals and Gubra announce collaboration within inflammatory bowel disease (IBD)<\/h2>\n[\/spb_boxed_content] [spb_blank_spacer height=&#8221;30px&#8221; width=&#8221;1\/1&#8243; el_position=&#8221;first last&#8221;] [spb_boxed_content type=&#8221;coloured&#8221; box_link_target=&#8221;_self&#8221; padding_vertical=&#8221;0&#8243; padding_horizontal=&#8221;0&#8243; width=&#8221;1\/1&#8243; el_position=&#8221;first last&#8221;]\n<p><strong>Saint-Prex, Switzerland and H\u00f8rsholm, Denmark \u2013 15 November 2022<\/strong> \u2013 Ferring Pharmaceuticals and Gubra entered into a collaboration agreement to further develop and characterize preclinical animal models of inflammatory bowel disease (IBD). <em>The collaboration aims to advance our early pipeline of targets in intestinal inflammation and fibrosis. Over the next year, we will conduct studies to help us understand the onset and progression of disease in preclinical models of IBD and validate tool compounds. In addition, Ferring and Gubra will collaborate to develop and standardise methods to assess fibrosis in the intestine, focusing on histological features that are translatable to human disease<\/em>.<\/p>\n<p><em>\u201cThis collaboration highlights Ferring\u2019s commitment to IBD and our ambition to develop better and more translatable models to support target validation\u201d,<\/em>\u00a0says Bryan Fuchs, VP Gastroenterology, Global Drug Discovery &amp; External Innovation. He adds: <em>\u201cGubra is a recognized preclinical research organization with expertise in digital imaging and AI quantification of fibrosis, so they are uniquely suited to partner with us in this endeavor.\u201d<\/em><\/p>\n<p>CEO at Gubra, Henrik Blou, expresses <em>\u201cIBD is a growing part of Gubra\u2019s disease focus, and we see this as an opportunity to make a difference, especially with a knowledgeable player like Ferring. We are thrilled with the collaboration and the possibility to unfold Gubra\u2019s wide palette of advanced digital methods and technologies to assess and quantify histological features of inflammation and fibrosis. Together with our competent partners at Ferring, we look forward to creating strong preclinical models that translate well into the clinic<\/em>.\u201d<\/p>\n[\/spb_boxed_content] [spb_blank_spacer height=&#8221;30px&#8221; width=&#8221;1\/1&#8243; el_position=&#8221;first last&#8221;] [spb_blank_spacer height=&#8221;30px&#8221; width=&#8221;1\/1&#8243; el_position=&#8221;first last&#8221;] [spb_boxed_content type=&#8221;coloured&#8221; box_link_target=&#8221;_self&#8221; padding_vertical=&#8221;0&#8243; padding_horizontal=&#8221;0&#8243; width=&#8221;1\/1&#8243; el_position=&#8221;first last&#8221;]\n<h3>About Ferring Pharmaceuticals:<\/h3>\n<p>Ferring Pharmaceuticals is a research-driven, specialty biopharmaceutical group committed to helping people around the world build families and live better lives. Headquartered in Saint-Prex, Switzerland, Ferring is a leader in reproductive medicine and maternal health, and in specialty areas within gastroenterology and urology. Ferring has been developing treatments for mothers and babies for over 50 years and has a portfolio covering treatments from conception to birth. Founded in 1950, privately-owned Ferring now employs around 6,000 people worldwide, has its own operating subsidiaries in nearly 60 countries and markets its products in 110 countries.<\/p>\n<p>Learn more at\u00a0<a href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.ferring.com%2F&amp;esheet=52743762&amp;newsitemid=20220609005091&amp;lan=en-US&amp;anchor=www.ferring.com&amp;index=1&amp;md5=0ddf2cc8291fe4d08611b2bfe705a289\">www.ferring.com<\/a>, or connect with us on\u00a0<a href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftwitter.com%2Fferring&amp;esheet=52743762&amp;newsitemid=20220609005091&amp;lan=en-US&amp;anchor=Twitter&amp;index=2&amp;md5=ee77e1d0df175efe419a312791acd6ec\">Twitter<\/a>,\u00a0<a href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.facebook.com%2Fferringpharmaceuticals%2F&amp;esheet=52743762&amp;newsitemid=20220609005091&amp;lan=en-US&amp;anchor=Facebook&amp;index=3&amp;md5=0647a3adc62154ed6ffc4f49fd6fb700\">Facebook<\/a>,\u00a0<a href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.instagram.com%2Fferringpharmaceuticals%2F&amp;esheet=52743762&amp;newsitemid=20220609005091&amp;lan=en-US&amp;anchor=Instagram&amp;index=4&amp;md5=6d56e3a64202d158834c9681a02f27ff\">Instagram<\/a>,\u00a0<a href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fferring-pharmaceuticals%2F&amp;esheet=52743762&amp;newsitemid=20220609005091&amp;lan=en-US&amp;anchor=LinkedIn&amp;index=5&amp;md5=a3dc0c00ce99ec453871129062b71df0\">LinkedIn<\/a>\u00a0and\u00a0<a href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.youtube.com%2Fchannel%2FUC6Ss0Uwv54xTGmM_EDEzQPA&amp;esheet=52743762&amp;newsitemid=20220609005091&amp;lan=en-US&amp;anchor=YouTube&amp;index=6&amp;md5=99f07a3e1adbb501fc459a7770955003\">YouTube<\/a>.<\/p>\n[\/spb_boxed_content] [spb_blank_spacer height=&#8221;30px&#8221; width=&#8221;1\/1&#8243; el_position=&#8221;first last&#8221;] [spb_boxed_content type=&#8221;coloured&#8221; box_link_target=&#8221;_self&#8221; padding_vertical=&#8221;0&#8243; padding_horizontal=&#8221;0&#8243; width=&#8221;1\/1&#8243; el_position=&#8221;first last&#8221;]\n<h3>About Gubra:<\/h3>\n<p>Gubra is a privately held biotech company since 2008, headquartered in Denmark. The company is a science and technology driven company with two primary areas of business: Preclinical contract research services (CRO) and proprietary early target and drug discovery programs. Gubra\u2019s primary focus is within the metabolic space (obesity, diabetes, NASH, CKD, CVD and diabetic complications) adding to this fibrotic disease areas such as IPF and IBD. Gubra specializes in <em>in vivo<\/em> pharmacology, peptide chemistry, molecular pharmacology, histology, 3D imaging, stereology, NGS (next generation sequencing), bioinformatics and <em>ex vivo<\/em> assays. High quality, scientific excellence, advanced digitalization, speed and solid teamwork, are key company traits which have established Gubra as a highly professional and competent partner in the market. Learn more at <a href=\"http:\/\/www.gubra.dk\">www.gubra.dk<\/a><\/p>\n[\/spb_boxed_content] [spb_blank_spacer height=&#8221;30px&#8221; width=&#8221;1\/1&#8243; el_position=&#8221;first last&#8221;] [spb_blank_spacer height=&#8221;30px&#8221; width=&#8221;1\/1&#8243; el_position=&#8221;first last&#8221;] [spb_boxed_content type=&#8221;coloured&#8221; box_link_target=&#8221;_self&#8221; padding_vertical=&#8221;0&#8243; padding_horizontal=&#8221;0&#8243; width=&#8221;1\/1&#8243; el_position=&#8221;first last&#8221;]\n<h3 style=\"color: #0088ce\">For more information please contact<\/h3>\n<p><strong>Ferring Pharmaceuticals<br \/>\nBj\u00f6rn Lindstr\u00f6m<br \/>\n<\/strong><em>Director, Corporate Communications &amp; Public Affairs<br \/>\n<\/em>+45 28 78 78 62<br \/>\n<a href=\"mailto:Bjoern.lindstroem@ferring.com\">Bjoern.lindstroem@ferring.com<\/a><\/p>\n<p><strong>Victoria Buenemann<br \/>\n<\/strong><em>Communications &amp; Business Manager, R&amp;D Strategy &amp; Operations<br \/>\n<\/em>+45 28 787 871 (mobile)<br \/>\n<a href=\"mailto:victoria.buenemann@ferring.com\">victoria.buenemann@ferring.com<\/a><\/p>\n<p><strong>Gubra<br \/>\nSofia Pitt Boserup<br \/>\n<\/strong>Lead Communication Partner<br \/>\n+45 41889586<br \/>\n<a href=\"mailto:sbo@gubra.dk\">sbo@gubra.dk<\/a><\/p>\n[\/spb_boxed_content] [spb_blank_spacer height=&#8221;30px&#8221; width=&#8221;1\/1&#8243; el_position=&#8221;first last&#8221;] [spb_row element_name=&#8221;Row&#8221; wrap_type=&#8221;content-width&#8221; parallax_image_height=&#8221;content-height&#8221; parallax_image_movement=&#8221;fixed&#8221; parallax_image_speed=&#8221;0.5&#8243; bg_video_loop=&#8221;yes&#8221; parallax_video_height=&#8221;window-height&#8221; parallax_video_overlay=&#8221;none&#8221; row_overlay_opacity=&#8221;0&#8243; row_col_pos=&#8221;default&#8221; minimize_row=&#8221;no&#8221; width=&#8221;1\/1&#8243; el_position=&#8221;first last&#8221;] [spb_button button_text=&#8221;READ MORE PRESS RELEASES&#8221; button_size=&#8221;standard&#8221; button_colour=&#8221;accent&#8221; button_type=&#8221;standard&#8221; rounded=&#8221;no&#8221; button_dropshadow=&#8221;no&#8221; button_link=&#8221;\/media\/press-releases\/&#8221; button_target=&#8221;_self&#8221; align=&#8221;center&#8221; animation=&#8221;none&#8221; animation_delay=&#8221;0&#8243; width=&#8221;1\/1&#8243; el_position=&#8221;first last&#8221;] [\/spb_row]\n","protected":false},"excerpt":{"rendered":"<p>[spb_boxed_content type=&#8221;coloured&#8221; box_link_target=&#8221;_self&#8221; padding_vertical=&#8221;0&#8243; padding_horizontal=&#8221;0&#8243; width=&#8221;1\/1&#8243; el_position=&#8221;first last&#8221;] Ferring Pharmaceuticals and Gubra announce collaboration within inflammatory bowel disease (IBD) [\/spb_boxed_content] [spb_blank_spacer height=&#8221;30px&#8221; width=&#8221;1\/1&#8243; el_position=&#8221;first last&#8221;] [spb_boxed_content type=&#8221;coloured&#8221; box_link_target=&#8221;_self&#8221; padding_vertical=&#8221;0&#8243; padding_horizontal=&#8221;0&#8243; width=&#8221;1\/1&#8243; el_position=&#8221;first last&#8221;] Saint-Prex, Switzerland and H\u00f8rsholm, Denmark \u2013 15 November 2022 \u2013 Ferring Pharmaceuticals and Gubra entered into a collaboration agreement to further develop and characterize preclinical animal models [&hellip;]<\/p>\n","protected":false},"author":4746,"featured_media":28675,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[1475],"tags":[],"class_list":["post-28674","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-press-release-2022"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.3 (Yoast SEO v23.3) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Ferring Pharmaceuticals and Gubra announce collaboration within Inflammatory Bowel Disease (IBD) - Ferring Global<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.ferring.com\/ferring-pharmaceuticals-and-gubra-announce-strategic-collaboration-within-inflammatory-bowel-disease-ibd\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Ferring Pharmaceuticals and Gubra announce collaboration within Inflammatory Bowel Disease (IBD)\" \/>\n<meta property=\"og:description\" content=\"[spb_boxed_content type=&#8221;coloured&#8221; box_link_target=&#8221;_self&#8221; padding_vertical=&#8221;0&#8243; padding_horizontal=&#8221;0&#8243; width=&#8221;1\/1&#8243; el_position=&#8221;first last&#8221;] Ferring Pharmaceuticals and Gubra announce collaboration within inflammatory bowel disease (IBD) [\/spb_boxed_content] [spb_blank_spacer height=&#8221;30px&#8221; width=&#8221;1\/1&#8243; el_position=&#8221;first last&#8221;] [spb_boxed_content type=&#8221;coloured&#8221; box_link_target=&#8221;_self&#8221; padding_vertical=&#8221;0&#8243; padding_horizontal=&#8221;0&#8243; width=&#8221;1\/1&#8243; el_position=&#8221;first last&#8221;] Saint-Prex, Switzerland and H\u00f8rsholm, Denmark \u2013 15 November 2022 \u2013 Ferring Pharmaceuticals and Gubra entered into a collaboration agreement to further develop and characterize preclinical animal models [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.ferring.com\/ferring-pharmaceuticals-and-gubra-announce-strategic-collaboration-within-inflammatory-bowel-disease-ibd\/\" \/>\n<meta property=\"og:site_name\" content=\"Ferring Global\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/ferringpharmaceuticals\/\" \/>\n<meta property=\"article:published_time\" content=\"2022-11-15T10:02:44+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2022-11-15T11:08:47+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/master-3.corporate.ferring.tech\/wp-content\/uploads\/sites\/16\/2022\/11\/ibd-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2048\" \/>\n\t<meta property=\"og:image:height\" content=\"1367\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"celia\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@ferring\" \/>\n<meta name=\"twitter:site\" content=\"@ferring\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"celia\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.ferring.com\/ferring-pharmaceuticals-and-gubra-announce-strategic-collaboration-within-inflammatory-bowel-disease-ibd\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.ferring.com\/ferring-pharmaceuticals-and-gubra-announce-strategic-collaboration-within-inflammatory-bowel-disease-ibd\/\"},\"author\":{\"name\":\"celia\",\"@id\":\"https:\/\/www.ferring.com\/#\/schema\/person\/3f52e318dbb73150503a8699dc63d3d0\"},\"headline\":\"Ferring Pharmaceuticals and Gubra announce collaboration within Inflammatory Bowel Disease (IBD)\",\"datePublished\":\"2022-11-15T10:02:44+00:00\",\"dateModified\":\"2022-11-15T11:08:47+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.ferring.com\/ferring-pharmaceuticals-and-gubra-announce-strategic-collaboration-within-inflammatory-bowel-disease-ibd\/\"},\"wordCount\":816,\"publisher\":{\"@id\":\"https:\/\/www.ferring.com\/#organization\"},\"image\":{\"@id\":\"https:\/\/www.ferring.com\/ferring-pharmaceuticals-and-gubra-announce-strategic-collaboration-within-inflammatory-bowel-disease-ibd\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/master-3.corporate.ferring.tech\/wp-content\/uploads\/sites\/16\/2022\/11\/ibd-scaled.jpg\",\"articleSection\":[\"PRESS RELEASE 2022\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.ferring.com\/ferring-pharmaceuticals-and-gubra-announce-strategic-collaboration-within-inflammatory-bowel-disease-ibd\/\",\"url\":\"https:\/\/www.ferring.com\/ferring-pharmaceuticals-and-gubra-announce-strategic-collaboration-within-inflammatory-bowel-disease-ibd\/\",\"name\":\"Ferring Pharmaceuticals and Gubra announce collaboration within Inflammatory Bowel Disease (IBD) - Ferring Global\",\"isPartOf\":{\"@id\":\"https:\/\/www.ferring.com\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.ferring.com\/ferring-pharmaceuticals-and-gubra-announce-strategic-collaboration-within-inflammatory-bowel-disease-ibd\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.ferring.com\/ferring-pharmaceuticals-and-gubra-announce-strategic-collaboration-within-inflammatory-bowel-disease-ibd\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/master-3.corporate.ferring.tech\/wp-content\/uploads\/sites\/16\/2022\/11\/ibd-scaled.jpg\",\"datePublished\":\"2022-11-15T10:02:44+00:00\",\"dateModified\":\"2022-11-15T11:08:47+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.ferring.com\/ferring-pharmaceuticals-and-gubra-announce-strategic-collaboration-within-inflammatory-bowel-disease-ibd\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.ferring.com\/ferring-pharmaceuticals-and-gubra-announce-strategic-collaboration-within-inflammatory-bowel-disease-ibd\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.ferring.com\/ferring-pharmaceuticals-and-gubra-announce-strategic-collaboration-within-inflammatory-bowel-disease-ibd\/#primaryimage\",\"url\":\"https:\/\/master-3.corporate.ferring.tech\/wp-content\/uploads\/sites\/16\/2022\/11\/ibd-scaled.jpg\",\"contentUrl\":\"https:\/\/master-3.corporate.ferring.tech\/wp-content\/uploads\/sites\/16\/2022\/11\/ibd-scaled.jpg\",\"width\":2048,\"height\":1367},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.ferring.com\/ferring-pharmaceuticals-and-gubra-announce-strategic-collaboration-within-inflammatory-bowel-disease-ibd\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.ferring.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Ferring Pharmaceuticals and Gubra announce collaboration within Inflammatory Bowel Disease (IBD)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.ferring.com\/#website\",\"url\":\"https:\/\/www.ferring.com\/\",\"name\":\"Ferring Pharmaceuticals\",\"description\":\"Helping people live better lives\",\"publisher\":{\"@id\":\"https:\/\/www.ferring.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.ferring.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.ferring.com\/#organization\",\"name\":\"Ferring\",\"url\":\"https:\/\/www.ferring.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.ferring.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/d2gohj824v350l.cloudfront.net\/wp-content\/uploads\/sites\/16\/2024\/01\/12104451\/Ferring-logo-7.png\",\"contentUrl\":\"https:\/\/d2gohj824v350l.cloudfront.net\/wp-content\/uploads\/sites\/16\/2024\/01\/12104451\/Ferring-logo-7.png\",\"width\":236,\"height\":154,\"caption\":\"Ferring\"},\"image\":{\"@id\":\"https:\/\/www.ferring.com\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/ferringpharmaceuticals\/\",\"https:\/\/x.com\/ferring\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.ferring.com\/#\/schema\/person\/3f52e318dbb73150503a8699dc63d3d0\",\"name\":\"celia\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.ferring.com\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/870a6ac667163f11e001926e332b8eb0?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/870a6ac667163f11e001926e332b8eb0?s=96&d=mm&r=g\",\"caption\":\"celia\"}}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Ferring Pharmaceuticals and Gubra announce collaboration within Inflammatory Bowel Disease (IBD) - Ferring Global","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.ferring.com\/ferring-pharmaceuticals-and-gubra-announce-strategic-collaboration-within-inflammatory-bowel-disease-ibd\/","og_locale":"en_US","og_type":"article","og_title":"Ferring Pharmaceuticals and Gubra announce collaboration within Inflammatory Bowel Disease (IBD)","og_description":"[spb_boxed_content type=&#8221;coloured&#8221; box_link_target=&#8221;_self&#8221; padding_vertical=&#8221;0&#8243; padding_horizontal=&#8221;0&#8243; width=&#8221;1\/1&#8243; el_position=&#8221;first last&#8221;] Ferring Pharmaceuticals and Gubra announce collaboration within inflammatory bowel disease (IBD) [\/spb_boxed_content] [spb_blank_spacer height=&#8221;30px&#8221; width=&#8221;1\/1&#8243; el_position=&#8221;first last&#8221;] [spb_boxed_content type=&#8221;coloured&#8221; box_link_target=&#8221;_self&#8221; padding_vertical=&#8221;0&#8243; padding_horizontal=&#8221;0&#8243; width=&#8221;1\/1&#8243; el_position=&#8221;first last&#8221;] Saint-Prex, Switzerland and H\u00f8rsholm, Denmark \u2013 15 November 2022 \u2013 Ferring Pharmaceuticals and Gubra entered into a collaboration agreement to further develop and characterize preclinical animal models [&hellip;]","og_url":"https:\/\/www.ferring.com\/ferring-pharmaceuticals-and-gubra-announce-strategic-collaboration-within-inflammatory-bowel-disease-ibd\/","og_site_name":"Ferring Global","article_publisher":"https:\/\/www.facebook.com\/ferringpharmaceuticals\/","article_published_time":"2022-11-15T10:02:44+00:00","article_modified_time":"2022-11-15T11:08:47+00:00","og_image":[{"width":2048,"height":1367,"url":"https:\/\/master-3.corporate.ferring.tech\/wp-content\/uploads\/sites\/16\/2022\/11\/ibd-scaled.jpg","type":"image\/jpeg"}],"author":"celia","twitter_card":"summary_large_image","twitter_creator":"@ferring","twitter_site":"@ferring","twitter_misc":{"Written by":"celia","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.ferring.com\/ferring-pharmaceuticals-and-gubra-announce-strategic-collaboration-within-inflammatory-bowel-disease-ibd\/#article","isPartOf":{"@id":"https:\/\/www.ferring.com\/ferring-pharmaceuticals-and-gubra-announce-strategic-collaboration-within-inflammatory-bowel-disease-ibd\/"},"author":{"name":"celia","@id":"https:\/\/www.ferring.com\/#\/schema\/person\/3f52e318dbb73150503a8699dc63d3d0"},"headline":"Ferring Pharmaceuticals and Gubra announce collaboration within Inflammatory Bowel Disease (IBD)","datePublished":"2022-11-15T10:02:44+00:00","dateModified":"2022-11-15T11:08:47+00:00","mainEntityOfPage":{"@id":"https:\/\/www.ferring.com\/ferring-pharmaceuticals-and-gubra-announce-strategic-collaboration-within-inflammatory-bowel-disease-ibd\/"},"wordCount":816,"publisher":{"@id":"https:\/\/www.ferring.com\/#organization"},"image":{"@id":"https:\/\/www.ferring.com\/ferring-pharmaceuticals-and-gubra-announce-strategic-collaboration-within-inflammatory-bowel-disease-ibd\/#primaryimage"},"thumbnailUrl":"https:\/\/master-3.corporate.ferring.tech\/wp-content\/uploads\/sites\/16\/2022\/11\/ibd-scaled.jpg","articleSection":["PRESS RELEASE 2022"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.ferring.com\/ferring-pharmaceuticals-and-gubra-announce-strategic-collaboration-within-inflammatory-bowel-disease-ibd\/","url":"https:\/\/www.ferring.com\/ferring-pharmaceuticals-and-gubra-announce-strategic-collaboration-within-inflammatory-bowel-disease-ibd\/","name":"Ferring Pharmaceuticals and Gubra announce collaboration within Inflammatory Bowel Disease (IBD) - Ferring Global","isPartOf":{"@id":"https:\/\/www.ferring.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.ferring.com\/ferring-pharmaceuticals-and-gubra-announce-strategic-collaboration-within-inflammatory-bowel-disease-ibd\/#primaryimage"},"image":{"@id":"https:\/\/www.ferring.com\/ferring-pharmaceuticals-and-gubra-announce-strategic-collaboration-within-inflammatory-bowel-disease-ibd\/#primaryimage"},"thumbnailUrl":"https:\/\/master-3.corporate.ferring.tech\/wp-content\/uploads\/sites\/16\/2022\/11\/ibd-scaled.jpg","datePublished":"2022-11-15T10:02:44+00:00","dateModified":"2022-11-15T11:08:47+00:00","breadcrumb":{"@id":"https:\/\/www.ferring.com\/ferring-pharmaceuticals-and-gubra-announce-strategic-collaboration-within-inflammatory-bowel-disease-ibd\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.ferring.com\/ferring-pharmaceuticals-and-gubra-announce-strategic-collaboration-within-inflammatory-bowel-disease-ibd\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.ferring.com\/ferring-pharmaceuticals-and-gubra-announce-strategic-collaboration-within-inflammatory-bowel-disease-ibd\/#primaryimage","url":"https:\/\/master-3.corporate.ferring.tech\/wp-content\/uploads\/sites\/16\/2022\/11\/ibd-scaled.jpg","contentUrl":"https:\/\/master-3.corporate.ferring.tech\/wp-content\/uploads\/sites\/16\/2022\/11\/ibd-scaled.jpg","width":2048,"height":1367},{"@type":"BreadcrumbList","@id":"https:\/\/www.ferring.com\/ferring-pharmaceuticals-and-gubra-announce-strategic-collaboration-within-inflammatory-bowel-disease-ibd\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.ferring.com\/"},{"@type":"ListItem","position":2,"name":"Ferring Pharmaceuticals and Gubra announce collaboration within Inflammatory Bowel Disease (IBD)"}]},{"@type":"WebSite","@id":"https:\/\/www.ferring.com\/#website","url":"https:\/\/www.ferring.com\/","name":"Ferring Pharmaceuticals","description":"Helping people live better lives","publisher":{"@id":"https:\/\/www.ferring.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.ferring.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.ferring.com\/#organization","name":"Ferring","url":"https:\/\/www.ferring.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.ferring.com\/#\/schema\/logo\/image\/","url":"https:\/\/d2gohj824v350l.cloudfront.net\/wp-content\/uploads\/sites\/16\/2024\/01\/12104451\/Ferring-logo-7.png","contentUrl":"https:\/\/d2gohj824v350l.cloudfront.net\/wp-content\/uploads\/sites\/16\/2024\/01\/12104451\/Ferring-logo-7.png","width":236,"height":154,"caption":"Ferring"},"image":{"@id":"https:\/\/www.ferring.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/ferringpharmaceuticals\/","https:\/\/x.com\/ferring"]},{"@type":"Person","@id":"https:\/\/www.ferring.com\/#\/schema\/person\/3f52e318dbb73150503a8699dc63d3d0","name":"celia","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.ferring.com\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/870a6ac667163f11e001926e332b8eb0?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/870a6ac667163f11e001926e332b8eb0?s=96&d=mm&r=g","caption":"celia"}}]}},"acf":[],"_links":{"self":[{"href":"https:\/\/www.ferring.com\/wp-json\/wp\/v2\/posts\/28674"}],"collection":[{"href":"https:\/\/www.ferring.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.ferring.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.ferring.com\/wp-json\/wp\/v2\/users\/4746"}],"replies":[{"embeddable":true,"href":"https:\/\/www.ferring.com\/wp-json\/wp\/v2\/comments?post=28674"}],"version-history":[{"count":12,"href":"https:\/\/www.ferring.com\/wp-json\/wp\/v2\/posts\/28674\/revisions"}],"predecessor-version":[{"id":28723,"href":"https:\/\/www.ferring.com\/wp-json\/wp\/v2\/posts\/28674\/revisions\/28723"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.ferring.com\/wp-json\/wp\/v2\/media\/28675"}],"wp:attachment":[{"href":"https:\/\/www.ferring.com\/wp-json\/wp\/v2\/media?parent=28674"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.ferring.com\/wp-json\/wp\/v2\/categories?post=28674"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.ferring.com\/wp-json\/wp\/v2\/tags?post=28674"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}